



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change.

**Effective Date: 08/12/2021**

**Yescarta™ (axicabtagene ciloleucel)**

**FDA approval:** 10/18/2017

**HCPCS:** Q2041

**Benefit:** Medical

**Policy:**

*Requests must be supported by submission of chart notes and patient specific documentation.*

- A. Coverage of the requested drug is provided when all the following are met:
- a. FDA approved age
  - b. Prescribed by or in consultation with an oncologist
  - c. Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (TFL)
    - i. Subjects must have received adequate prior therapy including at a minimum:
      1. Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20-negative and
      2. An anthracycline containing chemotherapy regimen
      3. For subjects with transformed FL must have received prior chemotherapy for follicular lymphoma and subsequently have chemorefractory disease after transformation to DLBCL
    - ii. Documentation of CD 19 tumor expression
    - iii. Do not have the following:
      1. Prior allogeneic HSCT
      2. Active central nervous system malignancy as determined by appropriate testing. Examples include: MRI and/or CSF analysis (including cytology plus molecular analysis, for example FISH)
      3. ECOG performance status of 2 or greater
      4. Absolute lymphocyte count less than 100/ $\mu$ L
      5. Creatinine clearance less than 60 mL/min
      6. Hepatic transaminases more than 2.5 times the upper limit of normal
      7. Cardiac ejection fraction less than 50%
      8. Active serious infection
  - d. Treatment of adult patients with relapsed or refractory follicular lymphoma (FL)

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

- i. Subjects must have received at least 2 prior lines of therapy one of which is an anti-CD20 monoclonal antibody combined with an alkylating agent
- ii. Must have measurable disease
- iii. Do not have any of the following:
  - 1. Prior allogeneic HSCT
  - 2. Active central nervous system malignancy as determined by appropriate testing. Examples include: MRI and/or CSF analysis (including cytology plus molecular analysis, for example FISH)
  - 3. ECOG performance status of 2 or greater
  - 4. Transformed FL
  - 5. Histological grade 3b FL
  - 6. Creatinine clearance less than 60 mL/min
  - 7. Hepatic transaminases more than 2.5 times the upper limit of normal
  - 8. Cardiac ejection fraction less than 50%
  - 9. Active serious infection
- e. Have not received prior treatment with any CAR-T therapy despite indication or any other genetically-modified T-cell therapy or are being considered for treatment with any other genetically-modified T-cell therapy
- f. Only to be administered at certified bone marrow/stem cell transplant centers
- g. Trial and failure, intolerance, or a contraindication to the preferred products as listed in the BCBSM/BCN utilization management medical drug list
- h. The prescriber needs to submit documentation of response to Yescarta within 3 months following therapy as a follow-up to the prior approval request
- i. If new diagnoses are FDA approved, coverage will be determined based on the FDA approved indication on a case by case basis until fully evaluated by the BCBSM Pharmacy and Therapeutics Committee

**B. Quantity Limitations, Authorization Period and Renewal Criteria**

- a. Quantity Limits: Align with FDA recommended dosing
- b. Authorization Period: 2 months with the allowance of only one dose per lifetime
- c. Renewal Criteria: Not applicable as no further authorization will be provided

\*\*\*Note: Coverage may differ for Medicare Part B members based on any applicable criteria outlined in Local Coverage Determinations (LCD) or National Coverage Determinations (NCD) as determined by Center for Medicare and Medicaid Services (CMS). See the CMS website at <http://www.cms.hhs.gov/>. Determination of coverage of Part B drugs is based on medically accepted indications which have supported citations included or approved for inclusion determined by CMS approved compendia.

**Therapeutic considerations:**

**A. FDA approved indication / Diagnosis**

*\*Please refer to most recent prescribing information.*

**B. Background Information**

- a. CAR-T therapy is a type of treatment that utilizes the body's own immune system to fight cancer. T-cells are collected from the patient via apheresis and are genetically engineered in the laboratory to produce chimeric antigen receptors on the cell surface, allowing the T-cells to recognize an antigen on target cancer cells. Once the tumor cells are identified, they are attacked and killed by the CAR-T therapy.

- b. CAR-T therapy has not been studied when given following prior treatment with any CAR-T therapy or following any other genetically-modified T-cell therapy.
- c. Due to the risk of cytokine release syndrome and neurological toxicities, CAR-T therapies are only allowed to be given at treatment centers certified by their REMS programs. CAR-T REMS programs require certified hospitals and their clinics to have on-site, immediate access to tocilizumab and an understanding of how to manage the risks of the associated CAR-T side effects.
- d. Yescarta is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. It is not indicated for the treatment of patients with primary central nervous system lymphoma. Yescarta is also indicated for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
- e. Efficacy was established in a single-arm, open-label, multicenter trial of 111 adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Of 111 patients who underwent leukapheresis, 101 received Yescarta. One patient did not receive the product due to manufacturing failure and 9 others were not treated due to progressive disease or serious adverse reactions. Yescarta was administered as a single intravenous infusion at a target dose of  $2 \times 10^6$  CAR-positive viable T-cells/kg. The lymphodepleting regimen consisted of cyclophosphamide 500 mg/m<sup>2</sup> intravenously and fludarabine 30 mg/m<sup>2</sup> intravenously given on the fifth, fourth, and third day before Yescarta. Patients with prior allogeneic HSCT, any history of central nervous system lymphoma, ECOG performance status of 2 or greater, absolute lymphocyte count less than 100/ $\mu$ L, creatinine clearance less than 60 mL/min, hepatic transaminases more than 2.5 times the upper limit of normal, cardiac ejection fraction less than 50%, or active serious infection were excluded. Subjects had previously received an anti-CD20 monoclonal antibody containing-regimen and an anthracycline-containing chemotherapy. Patients with transformed FL had received prior chemotherapy for follicular lymphoma and subsequently have chemorefractory disease after transformation to DLBCL. Primary endpoints were complete remission rate and duration of response. The median time to response was 0.9 months (range: 0.8 to 6.2 months). Of the 52 patients who achieved CR, 14 initially had stable disease (7 patients) or PR (7 patients), with a median time to improvement of 2.1 months (range: 1.6 to 5.3 months).
- f. Safety and efficacy for use in FL were established in the ZUMA-5 trial, an ongoing single-arm, open-label, multicenter phase 2 study of 104 adult patients with relapsed/refractory indolent NHL who had received up to 2 prior lines of therapy, including an anti-CD20 monoclonal antibody combined with an alkylating agent. Of the 104 patients, 84 had follicular lymphoma and 20 patients had marginal zone lymphoma and were required to have measurable disease. Patients were excluded if they had prior allogeneic HSCT, any history of central nervous system disease, ECOG performance status of 2 or greater, transformed FL, histological grade 3b FL, inadequate renal, hepatic, or cardiac function, or active serious infection. The primary endpoint is the objective response rate to therapy and key secondary endpoints include duration of response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events. After a median follow-up of 17.5 months, the objective response rate was 92% with 76% of patients reaching a complete response. When broken down by exact indication, 94% (n = 84) of patients with relapsed/refractory FL had an objective response including 80% achieving a complete response. Of patients with relapsed/refractory MZL (n=20), 85% had an objective response with 60% achieving a complete response. At the data cutoff, 62% of all treated patients had ongoing responses. Median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were not reached.

**C. Efficacy**

*\*Please refer to most recent prescribing information.*

**D. Medication Safety Considerations**

*\*Please refer to most recent prescribing information.*

**E. Dosing and administration**

*\*Please refer to most recent prescribing information.*

**F. How supplied**

*\*Please refer to most recent prescribing information.*

**References:**

1. Yescarta [prescribing information]. Santa Monica, CA: Kite Pharma, Inc.; April 2021.
2. LaRussa A. Chimeric antigen receptor (CAR) t-cell therapy. 10 Sept. 2015. Available at: [www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy](http://www.lls.org/treatment/types-of-treatment/immunotherapy/chimeric-antigen-receptor-car-t-cell-therapy). Access on August 3, 2017.
3. National Comprehensive Cancer Network. B-cell lymphomas (Version 4.2021). 2021 May 5. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/b-cell.pdf](https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf). Accessed on June 21, 2021.
4. Lee DW et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10; 124 (2): 188 - 195.

Policy History												
#	Date	Change Description										
1.2	Effective Date: 08/12/2021	New policy										
1.1	Effective Date: 03/08/2018	UM medical management system update for MAPPO and BCNA <table border="1" data-bbox="451 1249 1333 1459"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>Yes</td> </tr> <tr> <td>BCNA</td> <td>Yes</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	Yes	BCNA	Yes
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	Yes											
BCNA	Yes											
1.0	Effective Date: 01/01/2018	UM medical management system update for BCBS and BCN <table border="1" data-bbox="451 1535 1333 1745"> <thead> <tr> <th>Line of Business</th> <th>PA Required in Medical Management System (Yes/No)</th> </tr> </thead> <tbody> <tr> <td>BCBS</td> <td>Yes</td> </tr> <tr> <td>BCN</td> <td>Yes</td> </tr> <tr> <td>MAPPO</td> <td>No</td> </tr> <tr> <td>BCNA</td> <td>No</td> </tr> </tbody> </table>	Line of Business	PA Required in Medical Management System (Yes/No)	BCBS	Yes	BCN	Yes	MAPPO	No	BCNA	No
Line of Business	PA Required in Medical Management System (Yes/No)											
BCBS	Yes											
BCN	Yes											
MAPPO	No											
BCNA	No											

This policy and any information contained herein is the property of Blue Cross Blue Shield of Michigan and its subsidiaries, is strictly confidential, and its use is intended for the P&T committee, its members and BCBSM employees for the purpose of coverage determinations.

*\* The prescribing information for a drug is subject to change. To ensure you are reading the most current information it is advised that you reference the most updated prescribing information by visiting the drug or manufacturer website or <http://dailymed.nlm.nih.gov/dailymed/index.cfm>.*